S&P Futures
4,142.00+24.00(+0.58%)Dow Futures
33,782.00+158.00(+0.47%)Nasdaq Futures
13,931.25+132.50(+0.96%)
Electrovaya Inc. (EFLVF)
Chart Events
Performance Outlook
| Previous Close | 1.3000 |
| Open | 1.3200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.2500 - 1.3566 |
| 52 Week Range | 0.1300 - 2.1000 |
| Volume | 162,151 |
| Avg. Volume | 271,309 |
| Market Cap | 168.791M |
| Beta (5Y Monthly) | 2.06 |
| PE Ratio (TTM) | 142.33 |
| EPS (TTM) | 0.0090 |
| Earnings Date | Feb 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- ACCESSWIRE
Electrovaya Announces Commercial Launch of Its Electric Bus Battery
Delivers first 700V, 300kWh battery system for an electric busTORONTO, ON / ACCESSWIRE / March 17, 2021 / Electrovaya Inc. (TSX:EFL)(OTCQB:EFLVF) (the "Company") is pleased to announce the launch of its electric bus lithium ion battery systems with the delivery of a 700V, 300kWh battery.
- CNW Group
CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007
24, 2021 /CNW/ - The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that targets Prostate Specific Membrane Antigen (PSMA), a protein that is overexpressed in prostate cancer.
- ACCESSWIRE
Electrovaya, a Technology-Intensive Lithium Ion Battery Company, Applies to List on NASDAQ
TORONTO, ON / ACCESSWIRE / February 23, 2021 / Electrovaya Inc. ("Electrovaya" or the "Company") (TSX:EFL)(OTCQB:EFLVF), a lithium ion battery manufacturer with industry-leading performance and substantial intellectual property, has submitted an initial application to list its common shares on the Nasdaq Stock Market ("NASDAQ").
![CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007](https://s.yimg.com/uu/api/res/1.2/H.u3b2XLwkftip1U6RKkSA--~B/Zmk9c3RyaW07aD0xMjM7cT04MDt3PTIyMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/uu/api/res/1.2/3_0YGtYaAV9w1w8Wa2ASLg--~B/aD04MDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/cnwgroup.com/28be8498dfcceb3b47d101eefa81b5fd)
